miR-503, and miR-526) was associated with rapid disease progression with a 94% predictive value (7 ) .
The first miRNA to be described, lin-4, was inadvertently discovered in 1993 (8 ) ; however, the identification in 2000 of the miRNA let-7 and its ability to regulate lin-14 established this new class of regulatory nucleic acids and its potential value for disease diagnosis (9, 10 ) . Recently, miRNAs were noted to play a crucial role in the host's cellular response to viral infections (9, 11, 12 ) . In HIV-1 infections, most host miRNAs with altered production are downregulated. In addition, host miRNA profiles have been shown to contribute to distinct clinical outcomes (7 ) . These unique characteristics of circulating host miRNAs may provide alternative biomarkers for supplemental use in the diagnosis and prognosis of HIV-1 infections.
As pursued by the authors in their study, microarray-based techniques have proved useful for profiling miRNA production (7, 9, 13 ) . Moreover, quantitative real-time PCR (qPCR) methods have demonstrated high sensitivity and specificity with their ability to accurately detect and quantify miRNAs in a given sample (11 ) . This method has a considerably larger dynamic range than microarray analysis. qPCR has been adapted for increased throughput via the development of miRNA PCR arrays that can detect hundreds of miRNAs at once in a single reaction tube (11, 14 ) . The precision of miRNA analyses will be greatly improved with the added resolution of the RNA-Seq approach, using next-generation sequencing technologies for transcriptome profiling (15 ) .
Findings from this study have identified a distinct transcriptomic signature in peripheral blood mononuclear cells of RPs that should provide novel insights into the pathogenesis of HIV-1 infections. More importantly to the readers of Clinical Chemistry, the 5-miRNA panel discovered in this study opens up a new approach to the diagnosis of HIV-1 infections in clinical laboratories and evaluating the prognosis for HIV-1 infection. Although the results are promising, it is worth mentioning that the current study investigated only a relatively small number of highly selected HIV-1-infected patients, with CD4
ϩ cell counts at approximately 120 days after infection being the main effector. A large, multicenter cohort study with a longer follow-up that focuses on clinical outcomes will be needed to address these variables. Technically, the HIV-1 specificity remains uncertain when host miRNA molecules alone are used as biomarkers, because miRNAs are constantly regulated in various diseases and milieus. The best choice is likely to be a panel of miRNA molecules used in combination with other viral, genetic, and immunologic biomarkers. An integrated approach involving various techniques and disciplines would potentially be the most useful for rapid and accurate assessment of HIV-1 disease progression and prognosis. 
